Stock Events

Stock Events

AbCellera Biologics 

$3.57
569
+$0.2+5.93% Today

Statistics

Day High
3.59
Day Low
3.48
52W High
-
52W Low
-
Volume
355,207
Avg. Volume
-
Mkt Cap
1.07B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

7MayExpected
Q3 2025
Q4 2025
Next
-0.19
-0.14
-0.08
-0.03
Expected EPS
-0.156
Actual EPS
N/A

Financials

-194.88%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
150.26MRevenue
-292.82MNet Income

Analyst Ratings

$4.00Average Price Target
The highest estimate is 4.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
0%
Hold
100%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ABCL.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals competes in the discovery, development, and commercialization of treatments for serious medical conditions, similar to AbCellera's focus on antibody therapies.
Adaptive Biotechnologies
ADPT
Mkt Cap2.64B
Adaptive Biotechnologies offers immune-driven medicine solutions, directly competing with AbCellera's antibody discovery for therapeutic use.
Novavax
NVAX
Mkt Cap1.36B
Novavax is involved in the development of vaccines and therapeutics, which overlaps with AbCellera's work on antibody therapies for infectious diseases.
Moderna
MRNA
Mkt Cap10.61B
Moderna is known for its mRNA technology but also competes in the broader biotech space, including therapeutic antibodies, similar to AbCellera.
BioNTech
BNTX
Mkt Cap24.99B
BioNTech SE, while famous for its COVID-19 vaccine, also works on novel therapeutics, including antibodies, making it a competitor.
CRISPR Therapeutics
CRSP
Mkt Cap5.82B
CRISPR Therapeutics is engaged in gene editing, a cutting-edge area of biotech that could compete with antibody-based therapies offered by AbCellera.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Vertex Pharmaceuticals focuses on creating new therapies for serious diseases, a mission that aligns with AbCellera's, making them competitors in the biotech space.
Alnylam Pharmaceuticals
ALNY
Mkt Cap60.25B
Alnylam Pharmaceuticals specializes in RNAi therapeutics, a novel approach that could rival AbCellera's antibody-based treatments.
AMGEN
AMGN
Mkt Cap160.66B
Amgen is a biotechnology giant with a broad portfolio that includes antibody therapeutics, making it a competitor across several of AbCellera's areas of interest.

About

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635, an antibody-drug candidate, which is in preclinical trial to treat metabolic and endocrine conditions; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in preclinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
Show more...
CEO
ISIN
CA00288U1066

Listings

F
DE
8QQ.F
XNAS
US
ABCL
BOATS
BOATS
ABCL.BOATS

0 Comments

Share your thoughts

FAQ

What is AbCellera Biologics stock price today?▼
The current price of ABCL.BOATS is $3.57 USD — it has increased by +5.93% in the past 24 hours. Watch AbCellera Biologics stock price performance more closely on the chart.
What is AbCellera Biologics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange AbCellera Biologics stocks are traded under the ticker ABCL.BOATS.
What is AbCellera Biologics market cap?▼
Today AbCellera Biologics has the market capitalization of 1.07B
When is the next AbCellera Biologics earnings date?▼
AbCellera Biologics is going to release the next earnings report on May 07, 2026.
What were AbCellera Biologics earnings last quarter?▼
ABCL.BOATS earnings for the last quarter are -0.03 USD per share, whereas the estimation was -0.13 USD resulting in a +77.61% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is AbCellera Biologics revenue for the last year?▼
AbCellera Biologics revenue for the last year amounts to 150.26M USD.
What is AbCellera Biologics net income for the last year?▼
ABCL.BOATS net income for the last year is -292.82M USD.
When did AbCellera Biologics complete a stock split?▼
AbCellera Biologics has not had any recent stock splits.